RxDoctor Payments Data

Melissa Haggerty

Physician Assistant · Easton, PANPI 1881236016

Payments from drug & device makers

$8,828in general payments, 2019–2025

Across 387 payments — averaging $22.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$1K
  • Seagen Inc.$760
  • Johnson & Johnson$586
  • AstraZeneca$522
  • Incyte Corporation$513
  • Novartis$414
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$7,81088%
  • Education$1,01812%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.43$1,388
Seagen Inc.31$760
Johnson & Johnson(2 entities)19$586
AstraZeneca(2 entities)23$522
Incyte Corporation25$513
Novartis32$414
Daiichi Sankyo Inc.20$356
Pfizer9$311
Astellas Pharma US Inc13$263
AbbVie7$262
Ipsen Biopharmaceuticals, Inc8$230
Sanofi12$230
Pharmacyclics LLC, An Abbvie Company10$197
Bristol Myers Squibb11$184
Gilead(2 entities)10$170
Pharmacosmos Therapeutics Inc.2$147
G1 Therapeutics, Inc.2$143
Jazz Pharmaceuticals Inc.6$130
Lilly USA, LLC8$122
Epizyme, Inc.3$119
Foundation Medicine, Inc.3$118
Merck7$117
Bayer5$113
Amgen6$109
Eisai Inc.6$103
Karyopharm Therapeutics Inc.6$91
Genentech USA, Inc.4$77
GE HealthCare2$76
Rigel Pharmaceuticals, Inc.4$73
Sanofi-aventis U.S. LLC3$70
Taiho Oncology, Inc.3$53
Beigene USA, Inc.3$50
EMD Serono, Inc.3$49
Stemline Therapeutics Inc.2$48
Coherus Oncology, Inc.1$45
Tempus AI, Inc2$44
Blueprint Medicines Corporation2$43
Takeda Pharmaceuticals U.S.A., Inc.3$41
AMAG Pharmaceuticals, Inc.2$40
Sun Pharmaceutical Industries Inc.2$37
Dendreon Pharmaceuticals LLC2$33
Tersera Therapeutics LLC2$29
Dova Pharmaceuticals2$28
Helsinn Therapeutics (U.S.), Inc.2$28
Sobi, Inc1$24
Exelixis Inc.1$23
GSK1$22
TG Therapeutics, Inc.1$21
AVEO Pharmaceuticals, Inc.1$19
Organon1$17
Mylan Institutional Inc.1$17
Regeneron Healthcare Solutions, Inc.1$17
Agios Pharmaceuticals, Inc.1$16
Heron Therapeutics, Inc.1$15
Morphosys, US Inc.1$14
Bio Products Laboratory USA, Inc.1$13
Myovant Sciences Inc.1$13
Boehringer Ingelheim1$13
Servier Pharmaceuticals LLC1$12
Deciphera Pharmaceuticals Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,828 in reported general payments places this provider in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$27,996
Medicare patients
227
Services billed
335

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide35$406,131
ErleadaApalutamide20$292,159
RevlimidLenalidomide12$211,400
XtandiEnzalutamide12$166,656
ImbruvicaIbrutinib11$165,773
Abiraterone Acetate169$107,103
EliquisApixaban59$37,729
OrgovyxRelugolix12$32,582
XareltoRivaroxaban17$19,386
CreonLipase/Protease/Amylase11$16,924
Anastrozole34$1,438
Letrozole66$1,140
Ondansetron Hcl61$771
Exemestane11$771
Olanzapine28$735

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada, Xarelto$586$311,54537 claims
Bristol Myers SquibbRevlimid$184$211,40012 claims
Astellas Pharma US IncXtandi$263$166,65612 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$197$165,77311 claims
PfizerEliquis$311$37,72959 claims
AbbVieCreon$262$16,92411 claims
Lilly USA, LLCOlanzapine$122$73528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Easton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →